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come of interest was cost per decreased puff of rescue
medication per twenty eight days. RESULTS: Leval-
buterol (1.25 mg) decreased puffs by 7.5 over twenty
eight days. However, the average expected costs for treat-
ment with racemic albuterol (2.5 mg) is $116.94/month,
$171.46/month for levalbuterol (0.63 mg) and $182.33/
month for levalbuterol (1.25 mg). Cost-effectiveness ra-
tios were $8.35, $24.50, and $8.80 for albuterol (2.5
mg), levalbuterol (0.63 mg) and levalbuterol (1.25 mg),
respectively. Results were unchanged after sensitivity
analyses. CONCLUSIONS: Levalbuterol (1.25 mg) was
beneficial over racemic albuterol (2.5 mg) in decreasing
puffs of rescue medication over twenty eight days, but at
an additional cost. An incremental cost-effectiveness anal-
ysis demonstrated it costs $9.73 for each additional de-
creased puff per day. The decision-maker needs to evalu-
ate whether the additional effect is worth the added cost.
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OBJECTIVES: Despite their complexity appropriate use of
asthma inhaled medicines is crucial to ensure optimal drug
delivery to the airways. We describe the validation of an
instrument to assess inhalation skills in children. METH-
ODS: The instrument includes a breakdown of the steps
necessary for appropriate inhalation. We videotaped 25
children taking a placebo inhaler (metered dose inhaler
(MDI), MDI with AeroChamber® (MDI-AE®), and Dis-
kus®). A gold standard (GS) was developed by agreement
of two asthma experts watching the videotaped demon-
strations. Twenty-one raters scored the randomly ordered
demonstrations twice within a 2-week interval (sessions 1
and 2). Intra-class correlation coefficients (ICCs) were cal-
culated to assess validity (comparing GS to raters’ scores),
interrater reliability, and test-retest reliability for each step
of the inhalation. RESULTS: ICCs varied considerably by
both, the device and the step. In session 1, a small propor-
tion of raters agreed with the GS on whether patients actu-
ated the MDI and inhaled simultaneously (9.5%, ICCs
0.62 to 0.74) and whether patients hold their breath
(19%, ICCs 0.62 to 1.00). A better agreement was ob-
served for the MDI-AE® where actuation (43%, ICCs
0.43 to 0.56) and inhalation (57%, ICCs 0.43) are two
separate steps. The best interrater agreement was on the
shaking of the MDI (ICC  0.83) and the MDI-AE®
(ICC  0.74). Agreement for the Diskus® was poor for
all steps. Results for session 2 were similar. The best in-
tra-rater agreement was for the Diskus® (ICCs  1 for 5
steps), though only a small proportion of raters agreed on
these steps (5% to 21%). CONCLUSIONS: There was
large variability within and between raters’ scores. Some
steps were better assessed than others. These results sug-
gest that in addition to a detailed instrument, training of
raters is crucial to obtain a valid assessment of the child-
rens’ inhalation technique.
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OBJECTIVES: The study involved validating the scaling
properties of patient-physician interaction scale in a pul-
monary specialty clinic using a clinic-specific scale
through the implementation of Rasch analysis. DATA:
Cross-sectional data from 65 adult asthma patients at the
University of Illinois Asthma clinic was used. Physician
interaction was measured using eight Likert-type items.
Patients responded from “strongly disagree” (1) to
“strongly agree” (4). METHODS: Scaling properties
were assessed by investigating its fit to a Partial Credit
Rasch Rating scale model that enabled item-by-item anal-
ysis. Winsteps® was used for analysis. Model determined
scale robustness in terms of unidimensionality, additivity
and functioning of the rating scale. RESULTS: Analyses
found person separation index of 1.86 with reliability of
0.77. The mean patient measure (0.69 logit) was greater
than mean difficulty of items (0.00 logit) implying patient
ability was greater than item difficulty. On average, or-
dering of items found item ‘physician instructed patients
on home steroid treatment’ (STETX) had the highest
logit measure of 0.69, however it misfitted the model.
Item ‘physician asked about smoking habits’ (ASKSMOK)
had lowest measure of 0.70 logits. Fit statistics revealed
high infit and outfit mean square (MNSQ) values (1.4) for
16 patients. Seven items had MNSQ values within desired
range of 0.6–1.4. CONCLUSIONS: Items exhibited ade-
quate reliability in separating persons, but they displayed
ceiling and floor effects in measurement. Some evidence of
construct validity was established since only one item misfit-
ted the model. Item STETX was the most difficult to en-
dorse (higher on construct), since it might not be applicable
to all, but severe asthmatics. Item ‘ASKSMOK’ was easiest
to endorse, probably because it is a standard asthma care
question. Nevertheless, misfitting persons implied inappro-
priate measurement of some patient attitudes. Thus, some
plausibility in the unidimensionality and validity of the scale
existed, and it exhibited moderate scaling properties.
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OBJECTIVES: To prospectively evaluate the long-term
societal economic and humanistic benefits of acute treat-
ment of AECB with gemifloxacin compared with
clarithromycin. METHODS: Patients with AECB were
randomized to receive acute, double-blind, double-
dummy treatment with either gemifloxacin 320 mg o.d.
for 5 days or clarithromycin 500 mg b.d. for 7 days. Pa-
tients in US (n  386) and Canadian centers (n  52)
were followed for 26 weeks from treatment initiation and
the following assessments were made: AECB recurrence
requiring antibiotic treatment; respiratory tract infection-
related: health care resource utilization, time off and per-
formance at work and usual activities; and health-related
quality of life using the St George’s Respiratory Ques-
tionnaire (SGRQ). RESULTS: In full sample analysis, sig-
nificantly more patients who received gemifloxacin re-
mained recurrence free after 26 weeks (73.8% [158/214]
vs. 63.8% [143/224]; p  0.024) and were hospitalized
less (2.34% [5/214] vs. 6.25% [14/224]; p  0.059).
Cost-effectiveness analysis indicated average direct and
indirect cost savings of $329 per patient for gemifloxacin
vs. clarithromycin. Ninety-five percent confidence inter-
vals for bootstrapped incremental cost-effectiveness ra-
tios ranged from a cost saving of $14,175 to a cost of
$8,888 per recurrence-free patient considering all costs.
There was an 82.5% probability of gemifloxacin being
both cost saving and more effective than clarithromycin
from the societal perspective. A greater improvement in
total weighted SGRQ score (lower scores being better),
adjusted for baseline, was observed for gemifloxacin vs.
clarithromycin at 4, 12 and 26 weeks after initiation of
acute treatment (43.3 vs. 44.6 [p  0.38], 39.4 vs. 41.8
[p  0.20] and 37.7 vs. 41.0 [p  0.09], respectively).
There was significantly less impact on performance at
work (p  0.01) and usual activities (p  0.03) at 26
weeks, due to bronchitis, among patients who received
gemifloxacin. CONCLUSIONS: Gemifloxacin was very
cost-effective from the societal perspective and improved
long-term patient outcomes compared with clarithromy-
cin for the treatment of AECB.
PAR12
PROSPECTIVE USE OF WEB BASED 
TECHNOLOGY TO EVALUATE HEALTH 
OUTCOMES IN A LARGE COHORT OF SEVERE 
OR DIFFICULT TO TREAT ASTHMATICS
Dolan CM1, Fisher KA1, Johnson C1, Fraher KE1, Rothermich 
EA2, Fine JT1, Weiss ST3, Wenzel S4
1Genentech, Inc, South San Francisco, CA, USA; 2The Lewin 
Group, San Francisco, CA, USA; 3Harvard University, Boston, 
MA, USA; 4National Jewish Medical and Research Center, 
Denver, CO, USA
Severe and difficult to treat asthma patients represent a
small percentage of all asthmatics, yet they account for
much of the morbidity, mortality, and cost of the disease.
The factors that make this group of asthmatics difficult
to manage are poorly understood. OBJECTIVE: To es-
tablish a cohort of severe or difficult to treat asthmatics
to examine the relationships between features of asthma,
treatments and health outcomes using the Internet.
METHODS: This study, “An Observational Study of
The Epidemiology and Natural History of Asthma: Out-
comes and Treatment Regiments (TENOR),” is designed
to follow at least 5000 subjects for 3 years. Subjects 6
years or older with a diagnosis of asthma and considered
by their physician to have severe or difficult to treat
asthma are eligible for enrollment. Physicians and coordi-
nators will conduct biannual visits to collect data includ-
ing: health care utilization, days of work or school
missed, the asthma therapy assessment questionnaire
(ATAQ), asthma-related quality of life (AQLQ), medica-
tions, IgE level, and lung function. Data will be entered
onto a secure website. RESULTS: Subjects are being en-
rolled into the cohort from over 300 US pulmonologists
and allergists in managed care organizations, community
practices, and academic centers. All study sites have In-
ternet access. The TENOR website was built using Web-
CollectSM services and PhaseForward’s InFormTM ap-
plication. Built-in edit checks and an automatic electronic
audit trail ensure data accuracy and completeness. This
technology eliminates the need for paper case report
forms and improves data cleaning efficiency. CONCLU-
SIONS: TENOR provides a unique opportunity to exam-
ine factors related to poor health outcomes in this under-
studied patient population. The Internet allows real time
access to data and facilitates dissemination of data to in-
vestigators and the asthma community. TENOR may
serve as a model for future large epidemiologic or clinical
studies using web-based technology.
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OBJECTIVE: Despite increased use in the health care
sector (HCS), the contingent valuation (CV) method re-
mains controversial. The nucleus of the controversy is the
extent to which hypothetical choices in the CV method
mimic real economic choices. Correspondence between
hypothetical and real willingness to pay (WTP) has been
studied for private and environmental goods. These ex-
periments demonstrate that dichotomous choice (DC)
CV questions lead to hypothetical bias (overestimation of
real WTP). Hypothetical bias has not been assessed in the
HCS. We conducted an experiment directly comparing
responses to a DC CV question with real purchase deci-
sions using a pharmacist provided asthma management
